Rabies remains an invariably fatal neurological disease despite the availability of a preventive vaccination and post-exposure prophylaxis that must be immediately administered to the exposed individual before symptom onset. There is no effective medication for treatment during the symptomatic phase. Ribavirin, a guanine nucleoside analog, is a potent inhibitor of rabies virus (RABV) replication in vitro but lacks clinical efficacy. Therefore, we attempted to identify potential ribavirin analogs with comparable or superior anti-RABV activity. Antiviral activity and cytotoxicity of the compounds were initially examined in human neuroblastoma cells. Among the tested compounds, two exhibited a 5-to 27-fold higher anti-RABV activity than ribavirin. Examination of the anti-RABV mechanisms of action of the compounds using time-of-addition and minigenome assays revealed that they inhibited viral genome replication and transcription. Addition of exogenous guanosine to RABV-infected cells diminished the antiviral activity of the compounds, suggesting that they are involved in guanosine triphosphate (GTP) pool depletion by inhibiting inosine monophosphate dehydrogenase (IMPDH). Taken together, our findings underline the potency of nucleoside analogs as a class of antiviral compounds for the development of novel agents against RABV.
Introduction
Rabies is a vaccine-preventable infectious viral disease that damages the CNS of animals and humans. A post-exposure prophylaxis approved by World Health Organization involves the administration of rabies vaccine and immunoglobulin and is available to treat individuals exposed to RABV, but it must be administered before the clinical onset (Appolinario and Jackson, 2015; Rupprecht and Gibbons, 2004) . Despite a few reported cases of individuals surviving symptomatic rabies, including one case that was treated with the Milwaukee Protocol (Jackson, 2013) , it is extremely challenging to treat symptomatic patients. Once the virus reaches the CNS and neurological symptoms develop, the disease is invariably fatal. Known antiviral agents, such as amantadine and interferon alpha, failed to demonstrate therapeutic efficacy in a mouse model and clinical cases of RABV.
Only two nucleoside analogs have been sufficiently investigated for their anti-RABV effect. Ribavirin, a broad-spectrum guanine nucleoside analog, inhibited RABV replication in vitro but failed to demonstrate a protective efficacy in human clinical cases (Appolinario and Jackson, 2015; Bussereau et al., 1988; Warrell et al., 1989) . Favipiravir (T-705), the other nucleoside analog, exhibited potency as a rabies post-exposure prophylaxis in a mouse model (Yamada et al., 2016) , suggesting that nucleoside analogs could act as potential anti-RABV agents. Further study revealed that T-705 displayed limited use as a single treatment entity for rabies, and its use as a part of a multi-drug treatment remains unknown (Banyard et al., 2017) . Therefore, more compounds need to be identified to further pursue the potency of nucleoside analogs in rabies treatment, especially during the symptomatic phase of the disease.
The structure of nucleoside analogs resembles endogenous cellular nucleosides, critically required for nucleic acid biosynthesis, and they act as competitive inhibitors during viral genome replication (Jordheim et al., 2013) . The inhibitory mechanisms of action against viruses are thought to involve: (i) inhibition of inosine monophosphate dehydrogenase (IMPDH) function (Balzarini et al., 1993; Debing et al., 2014; Leyssen et al., 2005) , (ii) interference of viral genome replication by direct incorporation into nascent viral genomes thus inducing lethal mutagenesis (Baranovich et al., 2013; Crotty et al., 2000; Shah et al., 2010; Sun et al., 2007) , and (iii) inhibition of mRNA capping (Benarroch et al., 2004) .
Anti-RABV agents can be identified by examining compound libraries using either cell-based Chávez et al., 2006) or cell-free screening assays (Lingappa et al., 2013) . Cell-based systems using native RABV infection of susceptible cell lines have provided a more robust and replicable approach to identify anti-RABV compounds Bussereau and Ermine, 1983; Chávez et al., 2006) . Therefore, we employed a cell-based system using previously generated rRABV encoding Nluc (Anindita et al., 2016) . Several ribavirin analogs were tested. Their in vitro anti-RABV activity was compared to that of ribavirin to provide more detailed information with regards to the structure of chemical compounds provoking potent inhibitory effects on RABV replication.
Materials and methods

Cells and viruses
BHK clone 13 (BHK-21 [C-13]), human neuroblastoma (SK-N-SH), and mouse neuroblastoma (NA) cells were maintained in MEM supplemented with 10% FBS. HEK 293T cells were maintained in high glucose Dulbecco's modified MEM supplemented with 10% FBS.
Previously generated rRABV encoding Nluc, CVS-Nluc (N-P) (Anindita et al., 2016) , and rRABV encoding a wild type CVS genome, CVS-WT, were employed in this study. Virus stocks of CVS-Nluc (N-P) P.D. Anindita et al. Antiviral Research 154 (2018) 1-9 and CVS-WT were prepared in NA cells. Virus titers were determined using a focus forming assay.
Compounds
EICAR, EICNR, and BICAR were synthesized following previous study . Each compound was prepared and purified by crystallization or high-performance liquid chromatography (> 95%). Mizoribine was a generous gift from Asahi Chemical Industry Co., Ltd. (Tokyo, Japan). Ribavirin was purchased from Wako Pure Chemical Industries, Ltd., (Osaka, Japan). Guanosine, adenosine, cytidine, and uridine were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Infection experiments
SK-N-SH, NA, BHK, and HEK 293T cells seeded into 96-well plates on the previous day were treated with two-fold serially diluted compounds starting from 20 μM. The cells were then infected with CVSNluc (N-P) at an MOI of 0.1 or 1 for SK-N-SH or NA, BHK-21 [C-13] , and HEK 293T cells, respectively. The MOI was calculated as FFU/cell. Following incubation for 24 h, luciferase assay was performed using the Nano-Glo prior into 96-well plates were infected with CVS-Nluc (N-P) at an MOI of 0.1. Following 1 h incubation, the infected cells were treated with each compound in two-fold serial dilutions starting from 10 μM together with 30 μM nucleoside. The luciferase assay was performed at 24 hpi. Similar experiments were also performed to measure the anti-RABV activity of individual nucleosides.
Immunofluorescence assay
SK-N-SH cells were seeded into 96-well plates a day prior. Following treatment with the compounds for 1 h, the cells were inoculated with CVS-WT at an MOI of 5. After washing with PBS, they were incubated with fresh medium containing the compounds. At 16 hpi, the cells were fixed with 10% formaldehyde and stained with FITC-conjugated anti-RABV N antibody (Fujirebio Diagnostics, Inc., Malvern, PA, USA), and Hoechst 33342 (Molecular Probes, Eugene, OR, USA) was used to stain cell nuclei. The fluorescence signals were detected using an inverted fluorescence microscope, Olympus IX70 (Olympus, Tokyo, Japan).
Focus forming assay
NA cells seeded into 24-well plates were inoculated with virus P.D. Anindita et al. Antiviral Research 154 (2018) 1-9 stocks or culture supernatants from the infected cells diluted ten-fold. Following incubation for 1 h at 37°C on a plate shaker, an overlay medium containing MEM supplemented with 5% FBS; penicillin (100 U/ml), streptomycin (100 mg/ml), and 0.5% methylcellulose was added. Virus foci were detected using an FITC-conjugated anti-RABV N antibody (Fujirebio Diagnostics, Inc.) after 3 days of incubation. The number of foci was counted to determine the virus titer (FFU/ml).
Cell viability assay
Compound cytotoxicity was analyzed using the MTT assay following described procedure (Wada et al., 2017) . Cell monolayers were seeded in 96-well plates a day before treatment with two-fold serial dilutions of the compounds for 24 h incubation. Thereafter, MTT assay was performed and the absorbance at a 570 nm with a 630 nm reference wavelength was measured using an iMark™ Microplate Absorbance Reader (Bio-Rad, Hercules, CA, USA). The cell viability percentage was calculated by comparing the absorbance values of compound-treated and vehicle-treated groups.
Time-of-addition assays
To examine the effect of compounds on the viral attachment and entry stage, SK-N-SH cells seeded in 96-well plates were treated with 5 μM EICAR, 5 μM EICNR, or 50 μM ribavirin for 1 h at 37°C. After removal of culture medium, the treated cells were inoculated with CVSNluc (N-P) at an MOI of 0.1 for 1 h. At 16 hpi, the cells were harvested and assayed for luciferase.
To determine whether the compounds possess direct virucidal activity, CVS-Nluc (N-P) was incubated with EICAR or EICNR at a final concentration of 20 μM, or with ribavirin at a final concentration of 50 μM for 1 h at 37°C. Treated viruses were then used to infect confluent SK-N-SH cells seeded in 96-well plates at an MOI of 0.1. The infected cells were maintained in the absence of compounds and subsequently assayed for luciferase at 16 hpi.
The effect of the compounds in the viral post-entry stage was also examined. SK-N-SH cells seeded in 96-well plates were infected with CVS-Nluc (N-P) at an MOI of 0.1. After 1 h incubation at 37°C, the viral inoculum was removed and replaced by fresh culture medium. At different time points post-infection (0, 2, 4, 6, and 8 h), the culture medium was replaced with media containing 5 μM EICAR, 5 μM EICNR, or 50 μM ribavirin. The cells were then harvested at 16 hpi and assayed for luciferase.
Plasmid construction and RABV minigenome assay
Plasmids expressing Nluc-encoding minigenome of RABV-CVS (pCAGGS-RVDI-nluc) were generated following the construction strategy of firefly luciferase expressing pCAGGS-RVDI-luc (Okada et al., 2016) . As a result, RABV-CVS minigenome contains 5′ trailer region of RABV-CVS strain, an ORF of Nluc gene, the 3' leader region of RABV-CVS strain instead. Three helper plasmids encoding RABV proteins N, P (phosphoprotein), or L (polymerase) were also constructed. A PCRamplified fragment of N, P, or L genes containing an HA tag at the Cterminal end of each protein was inserted into pCXSN vectors. The resulting plasmids were designated pCXSN-N-HA(C), -P-HA(C), and -L-HA(C).
For the minigenome assay, NA cells seeded into 96-well plates were treated with serially diluted EICAR, EICNR, or ribavirin for 1 h, and then transfected with the RABV plasmids as follows: 20 ng pCAGGS-RVDI-Nluc, 120 ng pCXSN-N-HA(C), 12 ng pCXSN-P-HA(C), and 40 ng pCXSN-L-HA(C) using TransIT-Neural ® (Mirus Bio LLC, Madison, WI, USA). At 72 h post-transfection, the cells were harvested and assayed for luciferase.
Statistical analysis
Statistical analyses used ANOVA with Dunnett's post hoc test.
Results
Antiviral activity and cytotoxicity of nucleoside analogs
The antiviral activity of EICAR, EICNR, BICAR, mizoribine, and ribavirin ( Fig. 1) was examined using rRABV in SK-N-SH cells. The anti-RABV activity of ribavirin was previously demonstrated by the rRABV expression of Nluc (Anindita et al., 2016) . Thus, in the current study, ribavirin was used as a reference compound for RABV replication inhibition. The antiviral activity of each compound was indicated by a decrease in luciferase activity in serial dilutions of the compounds ( Fig. 2A-E) . EICAR, EICNR, BICAR, and ribavirin decreased the luciferase activity in a dose-dependent manner, while mizoribine did not exhibit anti-RABV activity. The EICAR-treated cells ( Fig. 2A) showed the most significant inhibition of luciferase activity. The calculated EC 50 values for EICAR, EICNR, BICAR, and ribavirin were 0.90, 3.80, 8.77, and 18.55 μM, respectively. No SK-N-SH cytotoxicity was observed (Fig. 2) .
Since EICAR and EICNR demonstrated greater anti-RABV activity 
Confirmation of EICAR and EICNR antiviral activity
Immunofluorescence assays allowed direct visualization of the inhibition by EICAR, EICNR, and ribavirin on native RABV infection. All compounds demonstrated unambiguous inhibition (Fig. 3, left panels) . Treatment of CVS-WT-infected SK-N-SH cells with each serially diluted compound revealed that they reduced the viral titers in the culture supernatants compared to DMSO-treated RABV-infected cells at 16 hpi. EICAR was the most effective anti-RABV compound ( Fig. 3B-D ; right panels).
Time-of-addition effect of EICAR and EICNR on RABV life cycle
To further determine the stage of the RABV life cycle that is inhibited by EICAR and EICNR treatment, we conducted time-of-addition assays. Treatment of SK-N-SH cells with EICAR, EICNR, or ribavirin prior to rRABV infection did not reveal any significant difference in luciferase activity (p ≥ 0.05), although a decrease of luciferase activity was observed in EICAR and ribavirin-treated cells (Fig. 4A) . The possibility of direct virucidal activity of EICAR, EICNR, and ribavirin was assessed by treating rRABV with each compound prior to virus inoculation into SK-N-SH cells. No significant decrease of luciferase activity compared to the DMSO-treated control was observed (Fig. 4B , p ≥ 0.05).
Inhibition of RABV replication after cell binding and entry was investigated by inoculation of SK-N-SH cells rRABV followed by treatment with EICAR, EICNR or ribavirin at different time points after inoculation (from 0 to 8 hpi). The cells were harvested for luciferase assay at 16 hpi. EICAR treatment at 0-6 hpi significantly decreased luciferase activity ( Fig. 4C ; 0-4 hpi, p < 0.001; 6 hpi, p < 0.01). In contrast, EICNR only demonstrated significant inhibition of RABV replication when treated at 0 hpi ( Fig. 4D ; p < 0.01). Ribavirin demonstrated a significant inhibition when added to the cells at 0-2 hpi ( Fig. 4E ; 0 hpi, p < 0.001; 2 hpi, p < 0.01). Altogether, these data suggested that neither EICAR nor EICNR inhibited the viral attachment or entry stages and that they do not possess direct virucidal properties against RABV.
Inhibition of viral transcription and genome replication by EICAR and EICNR
Based on the performed experiments, the anti-RABV activity of EICAR and EICNR appeared to affect the virus after the attachment and entry stages. An RABV minigenome system was employed to determine whether EICAR and EICNR inhibited RABV transcription. The RABV-CVS minigenome plasmid expressing Nluc was co-transfected into NA cells together with helper plasmids encoding RABV N, P, and L, essential for RABV replication complex formation. Decreased Nluc expression demonstrated that all compounds exhibited a dose-dependent anti-RABV activity on viral transcription (Fig. 5) . Interestingly, EICAR showed significant inhibitory effects at all tested concentrations (0.2-5 μM, p < 0.001; Fig. 5A ). EICNR inhibited viral transcription at concentrations between 1.3 and 5 μM (1.3 μM, p < 0.01; 2.5-5 μM, p < 0.001; Fig. 5B ), while the inhibitory effects of ribavirin were at 6.3-50 μM (6.3 μM, p < 0.01; 12.5-50 μM, p < 0.001; Fig. 5C ). These results indicated that EICAR, EICNR, and ribavirin exert their anti-RABV activity through the inhibition of RABV at the transcription and replication stages. Both EICAR and EICNR were more potent than ribavirin. The anti-RABV activity of EICNR was more restricted to higher concentrations than those of EICAR in both the wild type and recombinant virus.
3.5. Reversal of anti-RABV activity of EICAR, EICNR, and ribavirin in the presence of exogenous guanosine Since EICAR and EICNR are structurally related to ribavirin, we supposed that these two compounds acted similarly to ribavirin which exert its antiviral activity by depletion of the GTP pool via IMPDH inhibition (Debing et al., 2014; Leyssen et al., 2005) . Therefore, we examined whether the addition of exogenous guanosine or other nucleosides (adenosine, cytidine, and uridine) would reverse the anti-RABV activity of EICAR, EICNR, and ribavirin. Firstly, we examined the potential anti-RABV activity of each nucleoside. RABV replication in SK-N-SH cells was not inhibited, even at the highest nucleoside concentration used in the experiment (100 μM), and no cytotoxicity was observed (Table 2) . A nucleoside addition assay was then conducted by treatment of RABV-infected SK-N-SH cells with EICAR, EICNR, or ribavirin in the presence of exogenous guanosine, adenosine, cytidine, or uridine. As shown in Table 3 , the addition of 30 μM guanosine was sufficient to reverse the anti-RABV activity of EICAR (EC 50 : > 10 μM), EICNR (EC 50 : > 10 μM), and ribavirin (EC 50 : > 100 μM). The presence of other nucleosides did not affect the anti-RABV activity of any compound (Table 3) .
Discussion
The lack of an approved effective drug to inhibit RABV infection after symptom onset poses a major global threat to human health. Therefore, there is an urgent need to identify new anti-RABV agents that can reduce rabies fatalities. Despite no apparent clinical efficacy observed in the administration of ribavirin (Appolinario and Jackson, 2015; Hemachudha et al., 2006; Warrell et al., 1989) , the use of such a nucleoside analog should be considered when attempting to identify novel antiviral agents that inhibit RABV infection. Modifications of the chemical structure of this drug class could conceivably elicit superior anti-RABV effects.
In the present study, the anti-RABV activity of four ribavirin-related nucleoside analogs (EICAR, EICNR, BICAR, and mizoribine) was initially examined in SK-N-SH cells. EICAR and EICNR demonstrated greater anti-RABV activity than ribavirin. Other studies have reported that EICAR displayed a stronger broad-spectrum antiviral activity compared to ribavirin against a number of RNA viruses, including vesicular stomatitis virus, a prototype rhabdovirus belonging to the same viral family as RABV (De Clercq et al., 1991; Leyssen et al., 2005; Shigeta et al., 1992) . Previous reports showed that EICAR had been determined a potent inhibitor of cell proliferation by inhibiting cellular DNA and RNA synthesis, but not protein synthesis, a phenomenon shared with ribavirin (De Clercq et al., 1991) and therefore the anti-RABV activity of EICAR, as well as EICNR which is structurally similar to EICAR, might be due to its direct effect on cellular metabolism. However, the cytotoxicity data from all tested cell lines indicates that the anti-RABV activities of EICAR and EICNR might not be related to this particular mechanism of action. On the other hand, mizoribine, a licensed immunosuppressive drug in Europe and Japan, failed to demonstrate anti-RABV activity although this compound has been reported to inhibit ortho-and paramyxoviruses to a lesser extent than EICAR and ribavirin in vitro (Kosugi et al., 1994) .
Along with ribavirin, EICAR and EICNR are potential compound models that inhibit RABV infection. Initial investigation of the antiviral targets of EICAR and EICNR revealed that they did not likely act at the viral entry step or directly inactivate the virus (Fig. 4A, B) . These compounds inhibited rRABV Nluc reporter gene expression when they were added to RABV-infected cells in the early stages of viral infection: post attachment and entry into the target cells (Fig. 4C-E) . Importantly, EICAR could decrease the expression of Nluc when the RABV-infected cells were treated until 6 hpi, thus suggesting the potency of EICAR usage after the infection has been established. These results imply that EICAR and EICNR might interfere directly with viral transcription in a similar manner as observed previously with EICAR and ribavirin in other RNA viruses (De Clercq et al., 1991; Leyssen et al., 2005; Shigeta et al., 1992) .
It is plausible that EICAR and EICNR inhibit RABV transcription in a similar manner to ribavirin (Appolinário et al., 2013; Bussereau and Ermine, 1983; Crotty et al., 2000) because both compounds are ribavirin analogs. Using an RABV minigenome assay system, we demonstrated that EICAR and EICNR were capable of blocking viral transcription by decreasing the Nluc expression in a dose-dependent manner (Fig. 5) . As ribavirin administration also decreased Nluc expression, this observation relates to a previous observation where ribavirin was found to dose-dependently inhibit RABV RNA and protein synthesis (Bussereau and Ermine, 1983) .
Previous studies have demonstrated that EICAR acts as an IMPDH inhibitor by a similar mechanism of action to that proposed for ribavirin (Leyssen et al., 2005; Shigeta et al., 1992) . Inside the cell, EICAR is metabolized to EICAR 5′-monophosphate, sharing a similar binding site on IMPDH as IMP (Balzarini et al., 1993 ). IMPDH inhibition reduces the level of guanine nucleotide pool. Evidence in support of this proposed mechanism has been provided by reversing the antiviral activity of EICAR and ribavirin with the addition of exogenous guanosine (Balzarini et al., 1993; Dal Pozzo et al., 2010; Debing et al., 2014; Jashés et al., 2000; Leyssen et al., 2005) . In our study, we demonstrated the reversal of the anti-RABV activity of EICAR, EICNR, and ribavirin in the presence of guanosine, suggesting that these compounds exerted their anti-RABV activity through GTP pool depletion, possibly by IMPDH inhibition. It would be useful to directly quantify the level of intracellular GTP during the treatment of RABV-infected cells with these compounds to directly clarify this point.
The marked difference between EICAR and ribavirin is a substitution of the N at position 2 of the triazole ring with an alkynyl-carbon moiety, while EICNR is the 4-cyano derivative of EICAR (Fig. 1 ). This structural difference might contribute to the enhancement of the anti-RABV activity of EICAR and EICNR compared to ribavirin. Further structure-activity relationship studies need to be performed to elucidate the detailed mechanism of anti-RABV activity of these compounds.
Altogether, these findings suggest that EICAR and EICNR are more potent anti-RABV compounds than ribavirin by inhibiting viral replication and transcription, which in turn reemphasizes the potency of nucleoside analogs as a class of compounds feasible for the development of human rabies treatment. Further investigations are required to determine the inhibitory effect of EICAR and EICNR on RABV replication in vivo using mice models of RABV infection.
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